Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab

Citations Over TimeTop 1% of 2018 papers

Abstract

Here, we compared complete responders (CR) to non-responders (NR) and partial 18 responders (PR) to identify predictors for response.In total, we analyzed 85 patients 19 from 4 GA²LEN urticaria centers of reference and excellence (UCAREs) (5), 43 CR, 20 23 PR, and 19 NR to omalizumab treatment (Table 1).Complete, partial and non-21 response was defined as the reduction of signs and symptoms by ≥90%, by ≥30% 22 but 10%-29 50%, and >50%-100% were regarded as low normal, mid normal, and high normal, 30 whereas total IgE levels of >100%-250%, >250%-1000%, and >1000% were 31 regarded as slightly elevated, moderately elevated, and highly elevated.Statistical 32 analyses were done with SPSS (IBM SPSS Statistics, Version 22).33 No differences were found between the three responder groups (CR, PR, and NR) 34 Page 1 of 9 Allergy upregulating activity as an immunological marker to predict response to treatment 121 with omalizumab in patients with symptomatic chronic urticaria.

Related Papers

• → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)50 cited
• → Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab(2014)20 cited
• Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
• → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
• → Genentech taps Affimed’s antibodies(2018)